MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

开始日期2025-10-15

申办/合作机构

Mayo Clinic

NCT06445907

/ Recruiting临床1期

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.

开始日期2025-02-12

申办/合作机构

Qurient Co., Ltd.

NCT05438420

/ Recruiting临床1/2期

A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

开始日期2023-01-12

申办/合作机构

Qurient Co., Ltd.

[+1]

100 项与 Adrixetinib 相关的临床结果

登录后查看更多信息

100 项与 Adrixetinib 相关的转化医学

登录后查看更多信息

100 项与 Adrixetinib 相关的专利（医药）

登录后查看更多信息

项与 Adrixetinib 相关的文献（医药）

Cancers

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

Article

作者: Kim, Jeongjun ; Jeon, Yeejin ; Choi, Baejung ; Yang, Yeongin ; Kim, Jaeseung ; Kang, Hwankyu ; Nam, Kiyean ; Park, Dongsik

Although immune checkpoint blockade (ICB) represents a major breakthrough in cancer immunotherapy, only a limited number of patients with cancer benefit from ICB-based immunotherapy because most immune checkpoint inhibitors (ICIs) target only T cell activation. Therefore, targeting non-T cell components in the tumor microenvironment (TME) can help subvert resistance and increase the applications of ICB-based therapy. Axl and Mer are involved in the carcinogenesis of multiple types of cancer by modulating immune and biological behaviors within tumors. Colony stimulating factor 1 receptor (CSF1R) mediates tumorigenesis in the TME by enhancing tumor associated macrophage (TAM) and myeloid-derived suppressor cell (MDSC) infiltration, facilitating immune escape. Therefore, the simultaneous inhibition of Axl, Mer, and CSF1R kinases may improve therapeutic efficacy by targeting non-T cell components in the TME. Here, we present Q702, a selective, potent small molecule inhibitor targeting Axl, Mer, and CSF1R, for oral administration. Q702 induced antitumor activity in syngeneic tumor mouse models by: remodeling the TME toward immune stimulation; expanding M1 macrophage and CD8 T cell populations and decreasing M2 macrophage and MDSC populations in the TME; and increasing MHC class I and E-cadherin expression in tumor cells. Thus, Q702 may have great potential to broaden the coverage of populations benefiting from ICB-based immunotherapy.

项与 Adrixetinib 相关的新闻（医药）

2025-01-05

·药明康德

首次被证明口服依然有效的抗体疗法；可穿越血脑屏障的TYK2变构抑制剂… | 一周盘点

▎药明康德内容团队编辑本期看点 1. 用于治疗溃疡性结肠炎（UC）的口服抗体疗法达到1b期临床试验的主要目标，并在多个临床终点方面展现良好的活性。 2. 中枢神经系统（CNS）渗透性TYK2抑制剂A-005取得积极的1期临床试验结果，具有良好的耐受性，并能穿越血脑屏障。 3. 用于治疗慢性乙型肝炎病毒（HBV）感染的下一代衣壳组装调节剂（CAM）ABI-4334在1b期临床试验中展现强力的抗病毒活性，28天使患者血浆HBV DNA平均降低了2.9 log IU/mL。药明康德内容团队整理 SOR102：公布1b期临床试验数据 Sorriso Pharmaceuticals公司公布了其针对溃疡性结肠炎患者的口服TNFα和IL-23双效生物制品SOR102的积极1b期临床试验结果。SOR102通过在发炎组织内部提供局部组合疗法，同时尽量减少全身暴露，有望通过同时阻断炎症性肠病的不同机制来提高疗效。此次公布的结果显示，该研究达到了主要目标，显示出良好的安全性和耐受性。此外，关键的探索性疗效终点结果显示，SOR102在多个临床终点方面具有良好的活性。具体表现为，在完成研究的患者中，高剂量SOR102组患者在多个临床终点上与安慰剂组患者相比达到了统计学上的显著差异，包括Mayo评分临床缓解、改良Mayo评分临床缓解、症状缓解，以及Mayo评分、改良Mayo评分和UC-100评分与基线相比的平均下降值。新闻稿指出，该研究结果首次成功证明了口服抗体能够产生临床疗效。 A-005：公布1期临床试验数据 Alumis公司公布了其强效、选择性、CNS渗透性TYK2抑制剂A-005的1期临床试验的积极数据。新闻稿指出，A-005是首个公开的TYK2变构抑制剂。该候选疗法旨在实现最大的TYK2抑制效果，并能够穿越血脑屏障，在CNS内部和外周进行局部治疗，支持其在多个TYK2介导适应症中的潜力。该候选疗法正在开发用于治疗神经炎症和神经退行性疾病，如多发性硬化（MS）和帕金森病。此次公布的结果显示，A-005具有良好的耐受性，并能穿越血脑屏障。此外，A-005在CNS和外周实现了最大的TYK2抑制，并具有良好的药代动力学特征。基于这些数据，该公司预计在2025年下半年开始，在MS患者中进行2期临床试验。 ABI-4334：公布1b期临床试验数据 Assembly Biosciences公司公布了其在研下一代衣壳组装调节剂ABI-4334用于治疗慢性HBV感染患者的1b期临床试验数据。此次公布的结果显示，在首个150 mg剂量组中，ABI-4334显示出很强的抗病毒活性，在28天的治疗中，血浆HBV DNA平均降低了2.9 log IU/mL。此外，ABI-4334耐受性良好，具有良好的安全性，半衰期支持每日一次口服给药。 VYN202：公布1a期临床试验的新数据 VYNE Therapeutics公司公布了其口服小分子BET抑制剂VYN202的积极1a期临床试验结果。新闻稿指出，相对于BD1，VYN202对BD2具有潜在“class-leading”的选择性和效力。此次公布的结果显示，VYN202有潜力成为一种新型的、每日一次的口服药物，用于治疗广泛的免疫介导疾病。与1a期单剂量递增结果一致，VYN202展现了良好的安全性和耐受性特征，没有出现与早期选择性较低的BET抑制剂相关的药物相关不良事件。此外，VYN202在体外刺激试验中展现了强大的药理活性，包括靶点结合和显著抑制与几种免疫介导疾病相关的炎症生物标志物的证据。 MF-300：IND申请获得FDA许可 Epirium Bio公司宣布，美国FDA已批准其潜在“first-in-class”的口服15-羟基前列腺素脱氢酶（15-PGDH）抑制剂MF-300的IND申请，用于治疗肌肉减少症或年龄引起的肌无力。15-PGDH是一种能将前列腺素E2（PGE2）转化为非活性代谢物的酶。MF-300旨在可逆地结合到15-PGDH的PGE2结合位点上，阻止该酶转化PGE2。在生化试验中，MF-300能够抑制15-PGDH的活性。在临床前的细胞和动物研究中，MF-300可稳定和增加PGE2的水平。2024年12月，该公司已开始为MF-300的1期剂量递增研究招募患者。 Adrixetinib：IND申请获得FDA许可 Qurient宣布，美国FDA已批准其免疫肿瘤药物adrixetinib的IND申请，可开展针对慢性移植物抗宿主病（cGVHD）的1b期临床试验。Adrixetinib是一种针对Axl、Mer和CSF1R的选择性三重激酶抑制剂。这种药物能增强机体的免疫防御能力，提高癌细胞对治疗的敏感性。新闻稿指出，adrixetinib能够通过抑制CSF1R治疗cGVHD，并通过抑制Axl/Mer治疗白血病，这种双重作用机制有望为同时治疗这两种疾病提供潜在的益处。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看） [1] Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B. Retrieved December 26, 2024, from https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-interim-phase-1b-results-clinical [2] Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html [3] Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis. Retrieved December 19, 2024, from https://www.businesswire.com/news/home/20241219004563/en/Sorriso-Pharmaceuticals-Announces-Positive-Phase-1b-Clinical-Trial-Results-for-SOR102-in-Ulcerative-Colitis [4] VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor. Retrieved December 23, 2024, from https://www.globenewswire.com/news-release/2024/12/23/3001168/0/en/VYNE-Therapeutics-Reports-Positive-Top-line-Phase-1a-MAD-Data-for-VYN202-its-Novel-BD2-Selective-BET-Inhibitor.html [5] Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman. Retrieved December 23, 2024, from https://epirium.com/wp-content/uploads/2024/12/Epirium-Bio-Announces-FDA-Clearance-of-IND-Application-for-MF-300-and-Appointment-of-Alex-Casdin-as-New-CEO-and-Russell-Cox-as-Executive-Chairman.pdf [6] Qurient's Adrixetinib receives FDA IND approval for chronic graft-versus-host disease trial. Retrieved January 3, 2025, from https://www.koreabiomed.com/news/articleView.html?idxno=26208 [7] Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma. Retrieved December 19, 2024, from https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-provides-clinical-update-mt-601-patients [8] Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma. Retrieved December 19, 2024, from https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-first-patient-dosed-phase-1-clinical-trial [9] Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/3000160/0/en/Vittoria-Biotherapeutics-Announces-Dosing-of-First-Patient-in-Phase-1-Clinical-Trial-of-VIPER-101.html [10] Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/2999724/0/en/Arbor-Biotechnologies-Announces-FDA-Acceptance-of-IND-Application-for-ABO-101-for-the-Treatment-of-Primary-Hyperoxaluria-Type-1.html [11] RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial. Retrieved January 3, 2025, from https://www.globenewswire.com/news-release/2024/12/20/3000558/0/en/RAD-202-Receives-Approval-to-Start-Phase-1-Therapeutic-Trial.html [12] Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody. Retrieved January 3, 2025, from https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-first-participants-dosed-phase-1 [13] Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults. Retrieved January 3, 2025, from https://www.businesswire.com/news/home/20241218604766/en/Holoclara-Initiates-Phase-1-Clinical-Trial-Evaluating-Worm-Derived-Therapeutic-HC002-in-Healthy-Adults/ [14] SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections. Retrieved January 3, 2025, from https://ir.scynexis.com/news-events/press-releases/detail/342/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-a [15] Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME. Retrieved January 3, 2025, from https://www.immunocore.com/investors/news/press-releases/detail/105/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-p115c-a-half-life-extended-hle-immtac-candidate-in-patients-with-tumors-that-express-prame [16] Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease. Retrieved January 3, 2025, from https://gaintherapeutics.com/newsroom/press-releases/press-releases-2024/gain-therapeutics-initiates-phase-1b-clinical-trial-of-lead-candidate-gt-02287-in-people-with-gba1-and-idiopathic-parkinsons-disease/ [17] Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity. Retrieved January 3, 2025, from https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-of-aro-inhbe-for-the-treatment-of-obesity/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床2期临床结果临床1期

2023-02-03

·PRNewswire

Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent

Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections. Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license (except for South Korea, Russia and the Commonwealth of Independent States (CIS) countries) to develop and commercialize telacebec for the treatment of tuberculosis and some non-tuberculosis mycobacteria (NTM) infections. Kiyean Nam, Ph.D., CEO of Qurient, commented "As telacebec's unique mechanism of action of blocking energy metabolism of the Mycobacterium can address all types of TB, including drug-resistant TB, we expect telacebec to potentially become an essential component of drug combination regimens for the treatment of TB. We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide. Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need." Mel Spigelman, MD, President and CEO of TB Alliance, said "TB Alliance is excited to partner with Qurient to bring about the next generation of TB cures. New drugs like telacebec are urgently needed in the fight against TB as well as certain NTM infections – compounds with potentially impactful novel mechanisms of action can have a significant benefit in combating the TB pandemic. If we expect to regain ground lost to COVID-19, we need to use every tool we have to give patients the best possible treatment and save lives. We look forward to advancing this new compound as part of combination regimens that could yield a short, simple, safe, and highly effective cure for all forms of TB." About Telacebec (Q203) Telacebec is a first in class investigational drug that selectively inhibits the cytochrome bc1 complex of Mycobacterium tuberculosis. This complex is a critical component of the electron transport chain, and its inhibition disrupts the bacterium's ability to generate energy. The potent efficacy of telacebec against both drug sensitive and drug resistant TB has been demonstrated in preclinical and clinical studies. Telacebec was successfully tested in Phase 2a early bactericidal activity (EBA) study for tuberculosis and the results were published in the New England Journal of Medicine (March, 2020). Telacebec has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Tuberculosis is a tropical disease eligible for the FDA Priority Review Voucher (PRV) program. About Qurient Qurient is a clinical-stage biopharmaceutical company based in South Korea and is listed on the Korea Exchange (KRX 115180). Qurient focuses on the development of novel therapeutics from discovery to human proof-of-concept stages through virtual R&D project management platform. Qurient currently has four programs in clinical development: Q301, a topical leukotriene inhibitor for atopic dermatitis that has completed a Phase 2b study; telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis that has completed a Phase 2a study; Q702, a first-in-class Axl/Mer/CSF1R receptor tyrosine kinase inhibitor in Phase 1/2; and Q901, a selective CDK7 inhibitor in Phase 1. A subsidiary of Qurient, QLi5 is developing immunoproteasome inhibitors targeting multiple Myeloma and other indications. For more information, please visit . About TB Alliance TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Cystic Fibrosis Foundation, Germany's Federal Ministry of Education and Research through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Korea International Cooperation Agency, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Diseases, Netherlands Ministry of Foreign Affairs, South Korea's Ministry of Foreign Affairs, United Kingdom Department for International Development, and the United States Agency for International Development. For more information, please visit: SOURCE TB Alliance

临床2期孤儿药引进/卖出快速通道临床结果

2022-09-16

·BioSpace

Merck Capitalizes on Keytruda’s Combination Potential

With 33 approvals from the FDA, Merck’s checkpoint inhibitor Keytruda has become a powerhouse oncology drug and is likely to continue to rack up more regulatory wins. Courtesy of Kena Betancur/Getty Images With 33 approvals from the FDA across 16 tumor types, Merck’s checkpoint inhibitor Keytruda has become a powerhouse oncology drug and is likely to continue to rack up more regulatory wins. Keytruda was first approved by the FDA in 2014 and has become the cornerstone oncology drug for Merck. Last year, Keytruda (pembrolizumab) generated more than $17 billion for Merck, making it the second best-selling drug globally. The medication is slated to become the world’s top-selling drug by 2025 , according to analyst predictions. Merck continues to run its own programs assessing Keytruda, and multiple companies are also testing the medication in concert with their own assets. BioSpace outlines some of the more recent announcements regarding Keytruda combinations. Seagen-Astellas Pair Keytruda with Padcev for Urothelial Cancer At the European Society of Medical Oncology, Merck and partners Seagen and Astellas Pharma touted data from the cohort K of the Phase Ib/II EV-103 trial (KEYNOTE-869) evaluating Keytruda with bladder cancer drug Padcev (enfortumab vedotin-ejfv) as a first-line treatment for patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy. Cohort data showed patients who received the combination saw a 64.5% confirmed objective response rate. Of those, 10.5% of patients experienced a complete response, and 53.9% saw a partial response. The median duration of response was not reached. Additionally, the companies noted that in the combination arm, median progression-free survival was not reached. Median overall survival was 22.3 months. For patients who received Padcev alone, median PFS was eight months and median OS was 21.7 months. Marjorie Green, head of late-stage development at Seagen, noted in the announcement that nearly 65% of patients who received the combination study benefitted. Almost 11% showed no detectable cancer following treatment, she said. Jonathan E. Rosenberg, chief of genitourinary medical oncology service at Memorial Sloan Kettering, expressed his agreement, saying the combination could become an important therapeutic option for patients. Two years ago, the FDA granted the combination of Padcev and Keytruda Breakthrough Therapy designation for this indication. The companies said in a joint announcement that the data warrants further investigation for this patient line. Qurient Pairs Keytruda with its CDK7 Inhibitor Earlier this week, South Korea-based Qurient Co. Ltd. announced an agreement with Merck that pairs Keytruda with that company’s asset, Q901, a selective CDK7 inhibitor. Financial terms were not disclosed. Qurient is planning a Phase I/II study to assess the combination for the treatment of selected advanced solid tumors. It’s the second Qurient asset to be paired with Keytruda. The company is also assessing Keytruda with another one of its products, Q702. Kiyean Nam, chief executive officer of Qurient, said Q901 has shown “very effective tumor growth inhibition” through cell cycle regulation that triggers genomic instability. Nam noted that may “set synthetic lethality for anti-PD-1 therapy.” “The Q901 and anti-PD-1 antibody combination showed a beneficial effect in preclinical models, and we expect the same clinical benefits,” Nam said in a statement. Medicenna Looks to Keytruda Canada-based Medicenna Therapeutics also struck a Keytruda-centric deal with Merck this week. The company aims to study its beta-only, long-acting IL-2 super-agonist MDNA11 with Keytruda in a Phase I/II study. The ABILITY study will assess the pharmacokinetics, pharmacodynamics and preliminary efficacy of MDNA11 as a monotherapy and in combination with Keytruda in patients with advanced/metastatic solid tumors. The partnership between the companies includes the establishment of a Joint Development Committee that aims to advance the trial’s combination arm. MDNA11 is designed to selectively expand CD8 T and NK cells and increase PD-1 expression on immune cells. Fahar Merchant, president and CEO of Medicenna, said the agreement offers the opportunity to work with Merck, “the world’s leading immuno-oncology company.” The company believes MDNA11 has significant potential as a stand-alone treatment. Merchant stated that combining it with Keytruda “may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11.” Keytruda Combination in Prostate Cancer Data recently published in the Annals of Oncology and shared at ESMO revealed that Keytruda, in combination with standard of care abiraterone acetate and prednisone, produces anti-tumor activity in patients with metastatic castration-resistant prostate cancer who had not previously received chemotherapy for their cancer. According to the data, 56.3% of patients who received Keytruda in combination with standard of care achieved a confirmed prostate-specific antigen response. Additionally, the data shows that 81 of the 103 patients, 78.6%, saw a PSA reduction from baseline. This suggests adding Keytruda to the treatment regimen is safe and effective, the study authors wrote.

临床结果上市批准突破性疗法临床研究

100 项与 Adrixetinib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	Qurient Co., Ltd.	2023-01-12
晚期恶性实体瘤	临床2期	韩国	Qurient Co., Ltd.	2023-01-12
食管癌	临床2期	美国	Qurient Co., Ltd.	2023-01-12
食管癌	临床2期	韩国	Qurient Co., Ltd.	2023-01-12
肝细胞癌	临床2期	美国	Qurient Co., Ltd.	2023-01-12
肝细胞癌	临床2期	韩国	Qurient Co., Ltd.	2023-01-12
胃癌	临床2期	美国	Qurient Co., Ltd.	2023-01-12
胃癌	临床2期	韩国	Qurient Co., Ltd.	2023-01-12
宫颈癌	临床2期	美国	Qurient Co., Ltd.	2023-01-12
宫颈癌	临床2期	韩国	Qurient Co., Ltd.	2023-01-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04648254 (Q702, AACR2025)	临床1期	晚期恶性实体瘤 sAxl \| mCSF	51	Q702 14 mg	製鹽蓋艱鑰鬱襯衊蓋願(廠蓋製餘鏇鹽鏇醖鬱膚) = Treatment related AEs (TRAEs) in ≥10% of patients included AST/ALT increased 蓋糧鏇鑰壓襯遞淵製鏇 (獵顧蓋製獵廠鬱蓋積網 ) 更多	积极	2025-04-28
				Q702 120 mg
NCT04648254 (651, SITC2023)	临床1期	晚期恶性实体瘤	30	Q702 4mg	簾鬱餘選鹹製選簾蓋鏇(鹹齋觸顧膚鬱簾壓鏇糧) = 醖膚範齋齋夢選簾繭遞選蓋遞遞鬱鹽製鏇鑰鹽 (窪壓積膚淵構鏇淵鏇窪 ) 更多	积极	2023-11-02
				Q702 240mg	簾鬱餘選鹹製選簾蓋鏇(鹹齋觸顧膚鬱簾壓鏇糧) = 壓夢網淵構網獵簾壓糧選蓋遞遞鬱鹽製鏇鑰鹽 (窪壓積膚淵構鏇淵鏇窪 ) 更多